All Martin Shkreli articles
-
BusinessMartin Shkreli fined and banned from pharma for life
‘Pharma Bro’ must pay back $65m in profits for anticompetitive behaviour while leading Turing Pharmaceuticals
-
OpinionForged in righteous flames
Could the debate over pharma price-gouging have positive results for both patients and companies?
-
OpinionWhat the market will bear?
Martin Shkreli’s monopolising model poses some uncomfortable questions for the pharma industry, says Derek Lowe